<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00354432</url>
  </required_header>
  <id_info>
    <org_study_id>REBAcccwfu97405</org_study_id>
    <secondary_id>U10CA081851</secondary_id>
    <nct_id>NCT00354432</nct_id>
  </id_info>
  <brief_title>Soy Protein/Effexor Hormone Therapy for Prostate Cancer</brief_title>
  <official_title>Randomized Study of Soy Protein and Effexor on Vasomotor Symptoms of Men With Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wake Forest University Health Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Wake Forest University Health Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Soy protein/isoflavones and venlafaxine may help relieve hot flashes in patients
      receiving hormone therapy for prostate cancer. It is not yet known whether soy
      protein/isoflavones are more effective than venlafaxine when given together or with a placebo
      in treating hot flashes.

      PURPOSE: This randomized phase III trial is studying soy protein/isoflavones and venlafaxine
      to compare how well they work when given together or with a placebo in treating hot flashes
      in patients receiving hormone therapy for prostate cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  Assess the effect of soy protein/isoflavones and venlafaxine on the hot flash symptom
           severity score in patients undergoing hormonal manipulation for treatment of prostate
           cancer.

      Secondary

        -  Assess the effect of soy protein/isoflavones and venlafaxine on quality of life of these
           patients.

        -  Monitor and assess the participant drop out rate.

      OUTLINE: This is a randomized, double-blind, multicenter study. Patients are stratified
      according to severity of disease (metastatic vs nonmetastatic) and baseline severity of hot
      flashes. Patients are randomized to 1 of 4 treatment arms.

        -  Arm I: Patients receive oral placebo pill and oral soy protein/isoflavones powder once
           daily.

        -  Arm II: Patients receive oral venlafaxine and oral placebo powder once daily.

        -  Arm III: Patients receive oral venlafaxine and oral soy protein/isoflavones powder once
           daily.

        -  Arm IV: Patients receive oral placebo pill and oral placebo powder once daily. Treatment
           in all arms continues for 12 weeks in the absence of disease progression or unacceptable
           toxicity. After 12 weeks of treatment, patients in arms I and III receive a tapered dose
           of oral venlafaxine once daily for 1 week.

      Patients complete a vasomotor symptom diary once daily beginning 7 days before the initiation
      of study treatment and continuing until the completion of study treatment. Quality of life is
      assessed at baseline and at week 12.

      PROJECTED ACCRUAL: A total of 176 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Stopped by the DSMB for lack of effect per interim stopping rule.
  </why_stopped>
  <start_date>February 2007</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hot Flash Symptom Severity Score</measure>
    <time_frame>12 weeks</time_frame>
    <description>The primary objective of this randomized trial is to assess the effect of soy and Venlafaxine on the hot flash symptom severity score in men undergoing hormonal manipulation for treatment of prostate cancer. Hot flash severity will be quantitated using the symptom diary (as the sum of the number of hot flashes (any number greater than or equal to 0) times their severity (0=none, 1=mild, 2=moderate, 3=severe)). The primary end point is the 12 week hot flash score relative to the baseline value (i.e., 100*(12 week score)/baseline score). The range is 0 to infinity. Lower values represent a better outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>12 weeks</time_frame>
    <description>Quality of life is quantified by the Functional Assessment of Cancer Therapy - Prostate questionnaire (FACT-P). The FACT-P consists of four general subscales (functional, emotional, social, and physical) consisting of a total of 27 questions as well as a Prostate specific subscale consisting of 12 questions. Each question is answered on a 0 to 4 scale. The FACT-P score ranges from 0 to 156; higher scores denote better quality of life.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Hot Flashes</condition>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Arm I - Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive oral placebo pill and oral placebo powder once daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II - Soy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive oral placebo pill and oral soy protein/isoflavones powder once daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm III - Venlafaxine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oral Venlafaxine pill and placebo powder once daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm IV - Soy + Venlafaxine</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients receive oral Venlafaxine pill and soy protein/isoflavones powder once daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>oral soy protein/isoflavones powder</intervention_name>
    <description>Soy protein powder (20gm) orally 160 mg of total isoflavones isocaloric supplement of casein protein</description>
    <arm_group_label>Arm II - Soy</arm_group_label>
    <arm_group_label>Arm IV - Soy + Venlafaxine</arm_group_label>
    <other_name>Protein powder</other_name>
    <other_name>Supplement powder soy and casein 20gm</other_name>
    <other_name>Isoflavones</other_name>
    <other_name>Isocaloric supplement</other_name>
    <other_name>Casein protein</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Venlafaxine</intervention_name>
    <description>Patients receive oral venlafaxine 75mg.</description>
    <arm_group_label>Arm III - Venlafaxine</arm_group_label>
    <arm_group_label>Arm IV - Soy + Venlafaxine</arm_group_label>
    <other_name>Effexor XR</other_name>
    <other_name>placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo Powder</intervention_name>
    <description>Placebo powder (20gm casein protein) orally 0 mg of total isoflavones</description>
    <arm_group_label>Arm I - Placebo</arm_group_label>
    <arm_group_label>Arm III - Venlafaxine</arm_group_label>
    <other_name>Casein</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Pill</intervention_name>
    <description>Patients receive oral placebo pill.</description>
    <arm_group_label>Arm I - Placebo</arm_group_label>
    <arm_group_label>Arm II - Soy</arm_group_label>
    <other_name>Sugar Pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologic documentation of prostate cancer, any stage Life expectancy of &gt; nine
             months

          -  Prior or current androgen deprivation for treatment or control of prostate cancer to
             include:

          -  Bilateral Orchiectomy

          -  LHRH agonist (with or without antiandrogen therapy) ie: leuprolide (Lupron), goserelin
             (Zoladex), bicalutamide (Casodex), flutamide (Eulexin), or similar agents

          -  Chemotherapy

          -  Radiation (Patients may undergo concurrent radiation therapy to the prostate, prostate
             + seminal vesicles, and/or pelvis). Seed implants are allowed

          -  Participant report of hot flash frequency of an average of four or more per day, as
             defined by sweating, flushing, sensation of warmth, night sweats (Average of 28 per
             week)

          -  Hot flashes must be moderate or severe (See appendix A for hot flash definitions)

          -  Grade 2 (Moderate flashes) are warmer, produce obvious perspiration, and last 2 to 3
             minutes

          -  Grade 3 (Severe flashes) causes profuse perspiration, generate intense heat, last
             longer and interfere with ongoing activity

          -  Age &gt;21

          -  No allergies to soy or dairy products

          -  No current use of SSRIs, SNRI's, MAOIs, or Linezolide

          -  No uncontrolled hypertension (160/90) or greater than Class I American Heart
             Association functional capacity

          -  No history of mania, hypomania, bipolar disorder, or anorexia nervosa

          -  No history of seizures

          -  No history of hepatic dysfunction)

          -  Must have a telephone

          -  Signed protocol-specific Informed Consent

          -  Participants consuming soy foods or soy based supplements must continue on a stable
             regimen during study participation

          -  Patients should maintain same treatment and medications for prostate cancer throughout
             entire study.

          -  No change in treatment for 2 weeks prior to registration.

          -  Current use of medications and herbal supplements for hot flashes are allowed if on a
             stable regimen throughout the entire study. (Does not include anti-depressants)

        Exclusion Criteria:

          -  Anticipated changes in prostate cancer treatment plan (i.e., hormonal manipulation,
             changes in chemotherapy)

          -  Concurrent antidepressant therapy

          -  History of intolerance to venlafaxine

          -  Recent (within 14 days) use of venlafaxine (Effexor XRTM), monoamine oxidase
             inhibitor, SSRI (selective serotonin reuptake inhibitor), or SNRI (selective
             norepinephrine reuptake inhibitor)

          -  History of seizure disorder
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mara Vitolins, DrPH, RD</last_name>
    <role>Study Chair</role>
    <affiliation>Wake Forest University Health Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CCOP - Christiana Care Health Services</name>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <zip>19713</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MBCCOP - JHS Hospital of Cook County</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Central Illinois</name>
      <address>
        <city>Decatur</city>
        <state>Illinois</state>
        <zip>62526</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Northern Indiana CR Consortium</name>
      <address>
        <city>South Bend</city>
        <state>Indiana</state>
        <zip>46601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Cedar Rapids Oncology Project</name>
      <address>
        <city>Cedar Rapids</city>
        <state>Iowa</state>
        <zip>52403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MBCCOP - LSU Health Sciences Center</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Feist-Weiller Cancer Center at Louisiana State University Health Sciences</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71130-3932</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Michigan Cancer Research Consortium</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Beaumont</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073-6769</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Heartland Research Consortium</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - St. Louis-Cape Girardeau</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Cancer Research for the Ozarks</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alamance Cancer Center at Alamance Regional Medical Center</name>
      <address>
        <city>Burlington</city>
        <state>North Carolina</state>
        <zip>27216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southeastern Medical Oncology Center - Goldsboro</name>
      <address>
        <city>Goldsboro</city>
        <state>North Carolina</state>
        <zip>27534</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Caldwell Memorial Hospital</name>
      <address>
        <city>Lenoir</city>
        <state>North Carolina</state>
        <zip>28645</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest University Comprehensive Cancer Center</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157-1096</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest University CCOP Research Base</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Centers of the Carolinas - Easley</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29615</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Upstate Carolina</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>29303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - St. Vincent Hospital Cancer Center, Green Bay</name>
      <address>
        <city>Green Bay</city>
        <state>Wisconsin</state>
        <zip>54301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 19, 2006</study_first_submitted>
  <study_first_submitted_qc>July 19, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 20, 2006</study_first_posted>
  <results_first_submitted>July 15, 2015</results_first_submitted>
  <results_first_submitted_qc>April 12, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">May 18, 2017</results_first_posted>
  <last_update_submitted>November 27, 2017</last_update_submitted>
  <last_update_submitted_qc>November 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent prostate cancer</keyword>
  <keyword>stage I prostate cancer</keyword>
  <keyword>stage IIB prostate cancer</keyword>
  <keyword>stage IIA prostate cancer</keyword>
  <keyword>stage III prostate cancer</keyword>
  <keyword>stage IV prostate cancer</keyword>
  <keyword>hot flashes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Hot Flashes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Venlafaxine Hydrochloride</mesh_term>
    <mesh_term>Caseins</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Arm I - Placebo</title>
          <description>Patients receive oral placebo pill and oral placebo powder once daily.</description>
        </group>
        <group group_id="P2">
          <title>Arm II - Soy</title>
          <description>Patients receive oral placebo pill and oral soy protein/isoflavones powder once daily.</description>
        </group>
        <group group_id="P3">
          <title>Arm III - Venlafaxine</title>
          <description>Patients receive oral venlafaxine pill and oral placebo powder once daily.</description>
        </group>
        <group group_id="P4">
          <title>Arm IV - Soy + Venlafaxin</title>
          <description>Patients receive oral venlafaxine pill and oral soy protein/isoflavones powder once daily.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="30"/>
                <participants group_id="P3" count="30"/>
                <participants group_id="P4" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="22"/>
                <participants group_id="P3" count="20"/>
                <participants group_id="P4" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Off/Toxicity</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm I - Placebo</title>
          <description>Patients receive oral placebo pill and oral placebo powder once daily.</description>
        </group>
        <group group_id="B2">
          <title>Arm II - Soy</title>
          <description>Patients receive oral placebo pill and oral soy protein/isoflavones powder once daily.</description>
        </group>
        <group group_id="B3">
          <title>Arm III - Venlafaxine</title>
          <description>Patients receive oral venlafaxine pill and oral placebo powder once daily.</description>
        </group>
        <group group_id="B4">
          <title>Arm IV - Soy + Venlafaxine</title>
          <description>Patients receive oral venlafaxine pill and oral soy protein/isoflavones powder once daily.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
            <count group_id="B2" value="30"/>
            <count group_id="B3" value="30"/>
            <count group_id="B4" value="30"/>
            <count group_id="B5" value="120"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="43"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="19"/>
                    <measurement group_id="B5" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.8" spread="8.8"/>
                    <measurement group_id="B2" value="71.0" spread="8.2"/>
                    <measurement group_id="B3" value="67.8" spread="9.9"/>
                    <measurement group_id="B4" value="67.5" spread="9.1"/>
                    <measurement group_id="B5" value="68.5" spread="9.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="30"/>
                    <measurement group_id="B4" value="30"/>
                    <measurement group_id="B5" value="120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="30"/>
                    <measurement group_id="B4" value="30"/>
                    <measurement group_id="B5" value="120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Hot Flash Symptom Severity Score</title>
        <description>The primary objective of this randomized trial is to assess the effect of soy and Venlafaxine on the hot flash symptom severity score in men undergoing hormonal manipulation for treatment of prostate cancer. Hot flash severity will be quantitated using the symptom diary (as the sum of the number of hot flashes (any number greater than or equal to 0) times their severity (0=none, 1=mild, 2=moderate, 3=severe)). The primary end point is the 12 week hot flash score relative to the baseline value (i.e., 100*(12 week score)/baseline score). The range is 0 to infinity. Lower values represent a better outcome.</description>
        <time_frame>12 weeks</time_frame>
        <population>All randomized participants were analyzed in a repeated measures mixed model. This allowed inclusion of all study participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I - Placebo</title>
            <description>Patients receive oral placebo pill and oral placebo powder once daily.</description>
          </group>
          <group group_id="O2">
            <title>Arm II - Soy</title>
            <description>Patients receive oral placebo pill and oral soy protein/isoflavones powder once daily.</description>
          </group>
          <group group_id="O3">
            <title>Arm III - Venlafaxine</title>
            <description>Patients receive oral Venlafaxine pill and placebo powder once daily.</description>
          </group>
          <group group_id="O4">
            <title>Arm IV - Soy + Venlafaxine</title>
            <description>Patients receive oral Venlafaxine pill and soy protein/isoflavones powder once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Hot Flash Symptom Severity Score</title>
          <description>The primary objective of this randomized trial is to assess the effect of soy and Venlafaxine on the hot flash symptom severity score in men undergoing hormonal manipulation for treatment of prostate cancer. Hot flash severity will be quantitated using the symptom diary (as the sum of the number of hot flashes (any number greater than or equal to 0) times their severity (0=none, 1=mild, 2=moderate, 3=severe)). The primary end point is the 12 week hot flash score relative to the baseline value (i.e., 100*(12 week score)/baseline score). The range is 0 to infinity. Lower values represent a better outcome.</description>
          <population>All randomized participants were analyzed in a repeated measures mixed model. This allowed inclusion of all study participants.</population>
          <units>percent of baseline score</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.3" spread="10.8"/>
                    <measurement group_id="O2" value="77.2" spread="11.6"/>
                    <measurement group_id="O3" value="68.9" spread="12.1"/>
                    <measurement group_id="O4" value="73.8" spread="11.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was that there was no difference in the hot flash severity score at 12 weeks.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.3455</p_value>
            <p_value_desc>This p-value is not adjusted for multiple comparisons. The a priori threshold for statistical significance was 0.05.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>A mixed effects repeated measures analysis of variance was used with the baseline means constrained to be equal in the four groups.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life</title>
        <description>Quality of life is quantified by the Functional Assessment of Cancer Therapy - Prostate questionnaire (FACT-P). The FACT-P consists of four general subscales (functional, emotional, social, and physical) consisting of a total of 27 questions as well as a Prostate specific subscale consisting of 12 questions. Each question is answered on a 0 to 4 scale. The FACT-P score ranges from 0 to 156; higher scores denote better quality of life.</description>
        <time_frame>12 weeks</time_frame>
        <population>Participants with baseline and 12 week quality of life data.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I - Placebo</title>
            <description>Patients receive oral placebo pill and oral placebo powder once daily.</description>
          </group>
          <group group_id="O2">
            <title>Arm II - Soy</title>
            <description>Patients receive oral placebo pill and oral soy protein/isoflavones powder once daily.</description>
          </group>
          <group group_id="O3">
            <title>Arm III - Venlafaxine</title>
            <description>Patients receive oral Venlafaxine pill and placebo powder once daily.</description>
          </group>
          <group group_id="O4">
            <title>Arm IV - Soy + Venlafaxine</title>
            <description>Patients receive oral Venlafaxine pill and soy protein/isoflavones powder once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life</title>
          <description>Quality of life is quantified by the Functional Assessment of Cancer Therapy - Prostate questionnaire (FACT-P). The FACT-P consists of four general subscales (functional, emotional, social, and physical) consisting of a total of 27 questions as well as a Prostate specific subscale consisting of 12 questions. Each question is answered on a 0 to 4 scale. The FACT-P score ranges from 0 to 156; higher scores denote better quality of life.</description>
          <population>Participants with baseline and 12 week quality of life data.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="115.6" spread="2.4"/>
                    <measurement group_id="O2" value="121.5" spread="2.5"/>
                    <measurement group_id="O3" value="114.3" spread="2.7"/>
                    <measurement group_id="O4" value="117.7" spread="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis was that there was no difference in quality of life between the four groups at 12 weeks.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2081</p_value>
            <p_value_desc>This p-value is not adjusted for multiple comparisons. The a priori threshold for statistical significance was 0.05.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Arm I - Placebo</title>
          <description>Patients receive oral placebo pill and oral placebo powder once daily.</description>
        </group>
        <group group_id="E2">
          <title>Arm II - Soy</title>
          <description>Patients receive oral placebo pill and oral soy protein/isoflavones powder once daily.</description>
        </group>
        <group group_id="E3">
          <title>Arm III - Venlafaxine</title>
          <description>Patients receive oral Venlafaxine pill and placebo powder once daily.</description>
        </group>
        <group group_id="E4">
          <title>Arm IV - Soy + Venlafaxine</title>
          <description>Patients receive oral Venlafaxine pill and soy protein/isoflavones powder once daily.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Mood alteration - Agitation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Pain - Other</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Pain - chest NOS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" events="3" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection - Rectum</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain - joint</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Mood alteration- Anxiety</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Obstruction - Ureter</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Erectile Dysfunction</sub_title>
                <counts group_id="E1" events="6" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E2" events="13" subjects_affected="4" subjects_at_risk="27"/>
                <counts group_id="E3" events="8" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E4" events="13" subjects_affected="4" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Vascular - other</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" events="3" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="27" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="12" subjects_affected="6" subjects_at_risk="30"/>
                <counts group_id="E2" events="11" subjects_affected="5" subjects_at_risk="27"/>
                <counts group_id="E3" events="9" subjects_affected="7" subjects_at_risk="29"/>
                <counts group_id="E4" events="9" subjects_affected="5" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="23" subjects_affected="12" subjects_at_risk="30"/>
                <counts group_id="E2" events="11" subjects_affected="5" subjects_at_risk="27"/>
                <counts group_id="E3" events="15" subjects_affected="6" subjects_at_risk="29"/>
                <counts group_id="E4" events="29" subjects_affected="10" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Diarrhea - without colostomy</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="30"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E3" events="12" subjects_affected="5" subjects_at_risk="29"/>
                <counts group_id="E4" events="7" subjects_affected="3" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Distension/Bloating, Abdominal</sub_title>
                <counts group_id="E1" events="11" subjects_affected="6" subjects_at_risk="30"/>
                <counts group_id="E2" events="14" subjects_affected="7" subjects_at_risk="27"/>
                <counts group_id="E3" events="15" subjects_affected="10" subjects_at_risk="29"/>
                <counts group_id="E4" events="12" subjects_affected="6" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" events="28" subjects_affected="10" subjects_at_risk="30"/>
                <counts group_id="E2" events="16" subjects_affected="6" subjects_at_risk="27"/>
                <counts group_id="E3" events="10" subjects_affected="7" subjects_at_risk="29"/>
                <counts group_id="E4" events="22" subjects_affected="7" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="22" subjects_affected="11" subjects_at_risk="30"/>
                <counts group_id="E2" events="21" subjects_affected="9" subjects_at_risk="27"/>
                <counts group_id="E3" events="17" subjects_affected="9" subjects_at_risk="29"/>
                <counts group_id="E4" events="27" subjects_affected="11" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="9" subjects_affected="6" subjects_at_risk="30"/>
                <counts group_id="E2" events="8" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E3" events="6" subjects_affected="5" subjects_at_risk="29"/>
                <counts group_id="E4" events="15" subjects_affected="8" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic Reaction/hypersensitivity including drug reaction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="4" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="29"/>
                <counts group_id="E4" events="12" subjects_affected="5" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Constitutional Symptioms - Nightmares</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E3" events="5" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E4" events="9" subjects_affected="3" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="47" subjects_affected="18" subjects_at_risk="30"/>
                <counts group_id="E2" events="36" subjects_affected="11" subjects_at_risk="27"/>
                <counts group_id="E3" events="35" subjects_affected="18" subjects_at_risk="29"/>
                <counts group_id="E4" events="36" subjects_affected="15" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="45" subjects_affected="15" subjects_at_risk="30"/>
                <counts group_id="E2" events="20" subjects_affected="8" subjects_at_risk="27"/>
                <counts group_id="E3" events="26" subjects_affected="11" subjects_at_risk="29"/>
                <counts group_id="E4" events="26" subjects_affected="11" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Pain - Other</sub_title>
                <counts group_id="E1" events="38" subjects_affected="15" subjects_at_risk="30"/>
                <counts group_id="E2" events="43" subjects_affected="13" subjects_at_risk="27"/>
                <counts group_id="E3" events="32" subjects_affected="11" subjects_at_risk="29"/>
                <counts group_id="E4" events="19" subjects_affected="8" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Pain - Back</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Pain - Extremity - Limb</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Sweating - Diaphoresis</sub_title>
                <counts group_id="E1" events="61" subjects_affected="20" subjects_at_risk="30"/>
                <counts group_id="E2" events="64" subjects_affected="20" subjects_at_risk="27"/>
                <counts group_id="E3" events="63" subjects_affected="24" subjects_at_risk="29"/>
                <counts group_id="E4" events="74" subjects_affected="25" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain - joint</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Neurology - Nervousness</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E4" events="7" subjects_affected="3" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Neuropathy - Sensory</sub_title>
                <counts group_id="E1" events="7" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Mood Alteration - Agitation</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E2" events="10" subjects_affected="5" subjects_at_risk="27"/>
                <counts group_id="E3" events="10" subjects_affected="7" subjects_at_risk="29"/>
                <counts group_id="E4" events="12" subjects_affected="8" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Mood Alteration - Anxiety</sub_title>
                <counts group_id="E1" events="10" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E2" events="10" subjects_affected="4" subjects_at_risk="27"/>
                <counts group_id="E3" events="11" subjects_affected="6" subjects_at_risk="29"/>
                <counts group_id="E4" events="6" subjects_affected="3" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E4" events="7" subjects_affected="4" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal/Genitourinary - Other (Specify, __)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="5" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Urinary Frequency/Urgency</sub_title>
                <counts group_id="E1" events="5" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E2" events="4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E3" events="5" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E4" events="8" subjects_affected="3" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Ejaculatory Dysfunction</sub_title>
                <counts group_id="E1" events="58" subjects_affected="17" subjects_at_risk="30"/>
                <counts group_id="E2" events="36" subjects_affected="11" subjects_at_risk="27"/>
                <counts group_id="E3" events="39" subjects_affected="13" subjects_at_risk="29"/>
                <counts group_id="E4" events="36" subjects_affected="12" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Erectile Dysfunction</sub_title>
                <counts group_id="E1" events="62" subjects_affected="17" subjects_at_risk="30"/>
                <counts group_id="E2" events="42" subjects_affected="12" subjects_at_risk="27"/>
                <counts group_id="E3" events="37" subjects_affected="13" subjects_at_risk="29"/>
                <counts group_id="E4" events="32" subjects_affected="12" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Petechiae/purpura - hemorrhage/bleeding into skin or mucosa</sub_title>
                <counts group_id="E1" events="4" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="6" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" events="3" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="8" subjects_affected="4" subjects_at_risk="30"/>
                <counts group_id="E2" events="17" subjects_affected="8" subjects_at_risk="27"/>
                <counts group_id="E3" events="8" subjects_affected="4" subjects_at_risk="29"/>
                <counts group_id="E4" events="8" subjects_affected="3" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The study was stopped early by the DSMB due to a lack of effect.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Doug Case</name_or_title>
      <organization>Wake Forest University School of Medicine</organization>
      <phone>(336) 716-5425</phone>
      <email>dcase@wakehealth.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

